Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DEBRA L GRAYMAN

Allopathic & Osteopathic Physicians Dermatology

NPI
1962411462
CMS profile
361246
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$11,933.21

195 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DEBRA L GRAYMAN

NPI 1962411462 · CMS profile ID 361246

Allopathic & Osteopathic Physicians / Dermatology

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962411462?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DEBRA L GRAYMAN, NPI 1962411462, CMS profile ID 361246. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962411462?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DEBRA L GRAYMAN, NPI 1962411462, CMS profile ID 361246. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962411462?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DEBRA L GRAYMAN, NPI 1962411462, CMS profile ID 361246, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1962411462?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

195 matching records · $11,933.21 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 195 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 195.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $18.7906/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927184155 CMS
UCB, Inc. $13.8606/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908001373 CMS
ABBVIE INC. $9.8006/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892681937 CMS
Galderma Laboratories, L.P. $14.4206/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952274393 CMS
Amgen Inc. $18.9706/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939857415 CMS
Galderma Laboratories, L.P. $132.2806/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952274391 CMS
Janssen Biotech, Inc. $10.1606/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885727027 CMS
GENZYME CORPORATION $24.8306/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938953543 CMS
ABBVIE INC. $8.6706/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892681935 CMS
ABBVIE INC. $4.6706/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892681933 CMS
Janssen Biotech, Inc. $3.2206/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885727039 CMS
Novartis Pharmaceuticals Corporation $24.2206/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893713003 CMS
UCB, Inc. $11.8106/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908001369 CMS
PFIZER INC. $8.4105/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949647963 CMS
PFIZER INC. $10.5905/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949611923 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $13.2305/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947502493 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $10.5105/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947502499 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $0.8305/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947502501 CMS
Janssen Biotech, Inc. $89.9905/17/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885727011 CMS
Regeneron Healthcare Solutions, Inc. $26.6105/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927184149 CMS
MAYNE PHARMA INC. $12.3705/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959941705 CMS
Incyte Corporation $99.9905/15/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943001069 CMS
GENZYME CORPORATION $17.9905/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938953531 CMS
ABBVIE INC. $23.8905/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892681931 CMS
UCB, Inc. $16.7505/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908001375 CMS
Incyte Corporation $20.3305/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943001065 CMS
PFIZER INC. $11.4405/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949629455 CMS
ABBVIE INC. $5.0005/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892681929 CMS
MAYNE PHARMA INC. $11.3705/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959941721 CMS
Regeneron Healthcare Solutions, Inc. $65.0205/05/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927184145 CMS
Galderma Laboratories, L.P. $17.4205/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952274389 CMS
UCB, Inc. $16.7605/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908001377 CMS
ABBVIE INC. $9.4404/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892681927 CMS
Galderma Laboratories, L.P. $13.9504/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952274387 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $12.1304/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947502517 CMS
Allergan, Inc. $29.1604/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889897725 CMS
Galderma Laboratories, L.P. $24.5704/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952274385 CMS
MAYNE PHARMA INC. $11.7504/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959864683 CMS
Janssen Biotech, Inc. $3.0604/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885727055 CMS
PFIZER INC. $18.8304/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949630025 CMS
Galderma Laboratories, L.P. $5,400.0004/12/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 952274383 CMS
ABBVIE INC. $16.6704/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892681925 CMS
Regeneron Healthcare Solutions, Inc. $20.3404/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927184139 CMS
Almirall LLC $21.9804/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902847761 CMS
ABBVIE INC. $5.8804/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892681923 CMS
MAYNE PHARMA INC. $13.9003/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959855627 CMS
Incyte Corporation $9.2703/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943001057 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $9.9903/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947502515 CMS
GENZYME CORPORATION $24.6603/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938953509 CMS
PFIZER INC. $5.3003/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949623431 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $12,621.64 225
PY2020 $4,706.07 175
PY2021 $7,706.96 164
PY2022 $11,933.21 195
PY2023 $59,343.31 223
PY2024 $44,556.76 271
PY2025 $25,364.34 229

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $5,624.01 37
PY2023 Recipient $7,352.02 1
PY2023 Principal investigator $138,899.68 94
PY2022 Principal investigator $11,333.10 4
PY2021 Principal investigator $17,220.66 7
PY2020 Principal investigator $524,938.77 111
PY2019 Principal investigator $34,488.20 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $43.28 05/02/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710311
Principal investigator 1 Incyte Corporation $15.25 05/02/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710313
Principal investigator 1 Incyte Corporation $1.02 05/02/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710315
Principal investigator 1 Incyte Corporation $17.00 05/02/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710317
Principal investigator 1 Incyte Corporation $47.48 05/02/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710325
Principal investigator 1 Incyte Corporation $42.25 04/02/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710297
Principal investigator 1 Incyte Corporation $13.60 04/02/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710299
Principal investigator 1 Incyte Corporation $31.98 04/02/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710301
Principal investigator 1 Incyte Corporation $68.70 04/02/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710303
Principal investigator 1 Incyte Corporation $63.96 04/02/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710305
Principal investigator 1 Incyte Corporation $33.54 04/02/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710307
Principal investigator 1 Incyte Corporation $1.11 04/02/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710309
Principal investigator 1 Incyte Corporation $86.56 04/02/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710321
Principal investigator 1 Incyte Corporation $5.94 04/02/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710323
Principal investigator 1 Incyte Corporation $11.87 02/05/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710267
Principal investigator 1 Incyte Corporation $2.29 02/05/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710269
Principal investigator 1 Incyte Corporation $42.25 02/05/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710275
Principal investigator 1 Incyte Corporation $50.31 02/05/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710279
Principal investigator 1 Incyte Corporation $127.92 02/05/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710283
Principal investigator 1 Incyte Corporation $86.56 02/05/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710287
Principal investigator 1 Incyte Corporation $63.96 02/05/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710289
Principal investigator 1 Incyte Corporation $67.08 02/05/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710291
Principal investigator 1 Incyte Corporation $11.88 02/05/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710327
Principal investigator 1 Incyte Corporation $23.74 02/05/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710329
Principal investigator 1 Incyte Corporation $23.74 02/05/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710331
Principal investigator 1 Eli Lilly and Company $3,800.00 01/16/2024 Non-covered Recipient Entity
UNIVERSITY CLINICAL RESEARCH DELAND LLC
AN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AND SKIN OF COLOR No dispute reported 06/30/2026 1137370204
Principal investigator 1 Incyte Corporation $7.38 01/03/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710261
Principal investigator 1 Incyte Corporation $3.96 01/03/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710263
Principal investigator 1 Incyte Corporation $14.66 01/03/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710265
Principal investigator 1 Incyte Corporation $63.96 01/03/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710271
Principal investigator 1 Incyte Corporation $15.25 01/03/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710273
Principal investigator 1 Incyte Corporation $47.48 01/03/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710277
Principal investigator 1 Incyte Corporation $17.00 01/03/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710281
Principal investigator 1 Incyte Corporation $126.75 01/03/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710285
Principal investigator 1 Incyte Corporation $304.06 01/03/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710293
Principal investigator 1 Incyte Corporation $153.68 01/03/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710295
Principal investigator 1 Incyte Corporation $86.56 01/03/2024 Non-covered Recipient Entity
PURE SKIN DERMATOLOGY AESTHETICS AT ACCEL RESEARCH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134710319